Phase I/II Dose−Escalation Trial of Combination Fractionated-dose 177Lu−J591 and 177Lu−PSMA−617 in Patients With Metastatic Castration−Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary) ; PSMA 617 (Primary) ; Gallium 68 PSMA
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium.
- 30 Jul 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.